Stem Cell Research (Jul 2021)
Non-permissive SARS-CoV-2 infection in human neurospheres
- Carolina da S.G. Pedrosa,
- Livia Goto-Silva,
- Jairo R. Temerozo,
- Leticia R.Q. Souza,
- Gabriela Vitória,
- Isis M. Ornelas,
- Karina Karmirian,
- Mayara A. Mendes,
- Ismael C. Gomes,
- Carolina Q. Sacramento,
- Natalia Fintelman-Rodrigues,
- Vinicius Cardoso Soares,
- Suelen da Silva Gomes Dias,
- José A. Salerno,
- Teresa Puig-Pijuan,
- Julia T. Oliveira,
- Luiz G.H.S. Aragão,
- Thayana C.Q. Torquato,
- Carla Veríssimo,
- Diogo Biagi,
- Estela M. Cruvinel,
- Rafael Dariolli,
- Daniel R. Furtado,
- Helena L. Borges,
- Patrícia T. Bozza,
- Stevens Rehen,
- Thiago Moreno L. Souza,
- Marília Zaluar P. Guimarães
Affiliations
- Carolina da S.G. Pedrosa
- D’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
- Livia Goto-Silva
- D’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
- Jairo R. Temerozo
- National Institute for Science and Technology on Neuroimmunomodulation (INCT/NIM), Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil; Laboratory on Thymus Research, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil
- Leticia R.Q. Souza
- D’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
- Gabriela Vitória
- D’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
- Isis M. Ornelas
- D’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
- Karina Karmirian
- D’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
- Mayara A. Mendes
- D’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
- Ismael C. Gomes
- Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
- Carolina Q. Sacramento
- Immunopharmacology Laboratory, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil
- Natalia Fintelman-Rodrigues
- Immunopharmacology Laboratory, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil
- Vinicius Cardoso Soares
- Immunopharmacology Laboratory, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil; Program of Immunology and Inflammation, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
- Suelen da Silva Gomes Dias
- Immunopharmacology Laboratory, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil
- José A. Salerno
- D’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
- Teresa Puig-Pijuan
- D’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil; Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
- Julia T. Oliveira
- D’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
- Luiz G.H.S. Aragão
- D’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
- Thayana C.Q. Torquato
- D’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
- Carla Veríssimo
- Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
- Diogo Biagi
- Pluricell Biotech, São Paulo, SP, Brazil
- Estela M. Cruvinel
- Pluricell Biotech, São Paulo, SP, Brazil
- Rafael Dariolli
- Pluricell Biotech, São Paulo, SP, Brazil; Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Daniel R. Furtado
- D’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
- Helena L. Borges
- Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
- Patrícia T. Bozza
- National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil
- Stevens Rehen
- D’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil; Institute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil; Corresponding authors at: D’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil (S. Rehen and M.Z.P. Guimarães). National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil (T.M.L. Souza).
- Thiago Moreno L. Souza
- National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil; Program of Immunology and Inflammation, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil; Corresponding authors at: D’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil (S. Rehen and M.Z.P. Guimarães). National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil (T.M.L. Souza).
- Marília Zaluar P. Guimarães
- D’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil; Corresponding authors at: D’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil (S. Rehen and M.Z.P. Guimarães). National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil (T.M.L. Souza).
- Journal volume & issue
-
Vol. 54
p. 102436
Abstract
Coronavirus disease 2019 (COVID-19) was initially described as a viral infection of the respiratory tract. It is now known, however, that several other organs are affected, including the brain. Neurological manifestations such as stroke, encephalitis, and psychiatric conditions have been reported in COVID-19 patients, but the neurotropic potential of the virus is still debated. Herein, we sought to investigate SARS-CoV-2 infection in human neural cells. We demonstrated that SARS-CoV-2 infection of neural tissue is non-permissive, however, it can elicit inflammatory response and cell damage. These findings add to the hypothesis that most of the neural damage caused by SARS-CoV-2 infection is due to a systemic inflammation leading to indirect harmful effects on the central nervous system despite the absence of local viral replication.
